

Table SI. Studies included in the meta-analysis

Study/year	Design, country	Patients	Intervention	Outcome	Adverse effects
Chan et al. (25), 2013	RCT, Australia	<i>n</i> = 32 (M: 5/F: 14) (Type of IH Sup: 15) Sites Head and neck: 12 Trunk: 3 Extremities: 4	0.5% timolol BD (15/32) Placebo (17/23) Mean at initiation: 2.25 months Mean duration of Tx: 6 months	Assessed by photography > 5% decrease in volume in timolol: (9/15) > 5% decrease in volume in placebo: (2/16)	No significant side effects, no rebound
Moehrl et al. (32), 2013	Prospective case series, Germany	<i>n</i> = 11 (M: 5/F: 6) (Type of IH > 8 mm in size) Sites Head and neck: 4 Trunk: 2 Extremities: 5	0.5% timolol GFS under occlusion Mean at initiation: 3.89 months Mean duration of Tx: 3.64 months	Assessed by photography > 80% decrease in size: (7/11) 50–80% decrease in size: (4/11)	No significant side effects, no rebound
Ni et al. (33), 2011	Prospective case series, USA	<i>n</i> = 7 (Type of IH Sup: 7)	0.5% timolol BD Mean at initiation: 3 months Mean duration of Tx: 3 months	Assessed by photography Complete resolution (7/7)	No significant side effects, no rebound
Pope et al. (36), 2010	Prospective case series, Canada	<i>n</i> = 6 (Type of IH Sup: 6) Site Head and neck: 6	0.5% timolol BD Mean at initiation: 11.7 months Mean duration of Tx: 3.3 months	Mean VAS: (43.8 ± 23.2)	No significant side effects, no rebound
Oranje et al. (34), 2013	Prospective case series, Netherlands	<i>n</i> = 20 (Type of IH Sup: 8, Mix: 4, Deep: 8) Sites Periocular: 11 Head: 4 Nose: 2 Hand: 2 Arm: 1	0.5% timolol 3 to 4 times daily Mean at initiation: 3.65 months Mean duration of Tx: 3 months	Assessed by physician and caregivers Excellent: (7/20) Good: (9/20) Sufficient: (1/20) No response: (3/20)	No significant side effects, no rebound
Semkova et al. (39), 2013	Prospective case series, Bulgaria	<i>n</i> = 25 (M: 10/F: 15) (Type of IH Sup: 25) Sites Head and neck: 27 Trunk and Extremities: 12	0.1% timolol five times daily Mean at initiation: 3 months Mean duration of Tx: 2 months	Global assessment score (GAS) mean: 2.56 GAS-3 to 3, 0=no change, 3 complete resolution	No significant side effects, no rebound
Xu et al. (46), 2014	Prospective case series, China	<i>n</i> = 35 (M: 11/F: 24) (Type of IH Sup: 35) Sites Head and neck: 22 Trunk: 8 Extremities: 5	0.5% timolol BD Mean at initiation: 4.7 months Mean duration of Tx: 5.5 months	Assessed by photography Good: (18/35) Partial: (10/35) No response: (6/35)	No significant side effects, no rebound

RCT: randomised controlled trial; IH: infantile hemangioma; Sup: superficial; BD: twice daily; Tx: treatment; VAS: Visual Analogue Scale.